Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024

Rhea-AI Summary

Repare Therapeutics (Nasdaq: RPTX) announced that initial data from its Phase 1 MINOTAUR study will be presented at the European Society of Medical Oncology (ESMO) GI Congress 2024. The study evaluates the efficacy of lunresertib (RP-6306) in combination with FOLFIRI for treating advanced solid tumors. This presentation is scheduled for June 27, 2024, at 3:35 PM CEST in Munich, Germany. The study aims to offer new insights into advanced gastrointestinal cancer treatments.

Positive

• Initial data from Phase 1 MINOTAUR study to be presented at ESMO GI Congress 2024.
• Study evaluates promising combination of lunresertib (RP-6306) and FOLFIRI.
• Potential for new treatment insights in advanced gastrointestinal cancers.
• Presentation at a prestigious event could boost company visibility and credibility.

Negative

• Phase 1 study indicates early-stage clinical trials, which come with higher uncertainty and risk.
• No specific efficacy or safety results mentioned in the announcement.
• Potential delays or adverse results in further trials could impact stock performance.

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced initial data from the Phase 1 MINOTAUR study evaluating lunresertib (RP-6306) in combination with FOLFIRI for the treatment of advanced solid tumors has been selected for a poster presentation at the European Society of Medical Oncology (ESMO) Gastrointestinal (GI) Cancers Congress 2024, being held June 26-29 in Munich, Germany.

Details for the poster presentation are as follows:

Title: Phase 1 Study of the PKMYT1 Inhibitor Lunresertib (Lunre) in Combination with FOLFIRI in Advanced Gastrointestinal (GI) Cancers (MINOTAUR Study)
Speaker: Zev A. Wainberg, David Geffen School of Medicine at UCLA
Presentation Number: 504P
Date and Time: June 27, 2024 at 3:35 PM CEST

About Repare Therapeutics Inc.

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes lunresertib (also known as RP-6306), a PKMYT1 inhibitor currently in Phase 1/2 clinical development; camonsertib (also known as RP-3500), a potential leading ATR inhibitor currently in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical Polθ ATPase inhibitor program; as well as additional, undisclosed preclinical programs. For more information, please visit www.reparerx.com and follow @Reparerx on X (formerly Twitter) and LinkedIn.

SNIPRx® is a registered trademark of Repare Therapeutics Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240529691824/en/

Investor Relations & Media Contact:

Robin Garner

Vice President and Head of Investor Relations

Repare Therapeutics Inc.

investor@reparerx.com

Source: Repare Therapeutics Inc.

FAQ

What is the Phase 1 MINOTAUR study by Repare Therapeutics?

The Phase 1 MINOTAUR study evaluates lunresertib (RP-6306) in combination with FOLFIRI for treating advanced solid tumors.

When will Repare Therapeutics present the MINOTAUR study data?

Repare Therapeutics will present the data on June 27, 2024, at 3:35 PM CEST at the ESMO GI Congress.

What is the focus of the MINOTAUR study?

The focus is on the combination treatment of lunresertib (RP-6306) and FOLFIRI for advanced gastrointestinal cancers.

Where is the ESMO GI Congress 2024 held?

The ESMO GI Congress 2024 will be held in Munich, Germany.

Which company is behind the MINOTAUR study?

Repare Therapeutics (Nasdaq: RPTX) is conducting the MINOTAUR study.